{
    "organizations": [],
    "uuid": "d93a98e8241a18d3207ddf5ec080b06fd8069ec8",
    "author": "",
    "url": "https://www.reuters.com/article/brief-rigel-makes-statement-regarding-we/brief-rigel-makes-statement-regarding-website-error-idUSFWN1RP124",
    "ord_in_thread": 0,
    "title": "BRIEF-Rigel Makes Statement Regarding Website Error",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 12, 2018 / 8:04 PM / Updated 6 minutes ago BRIEF-Rigel Makes Statement Regarding Website Error Reuters Staff \nApril 12 (Reuters) - Rigel Pharmaceuticals Inc: * RIGEL MAKES STATEMENT REGARDING WEBSITE ERROR \n* FDA IS CONTINUING ITS REVIEW OF NDA AND PDUFA ACTION DATE FOR FOSTAMATINIB NDA IS APRIL 17 \n* DUE TO AN ERROR, INACCURATE INFORMATION WAS DISPLAYED REGARDING U.S. FDA’S REVIEW OF NDA FOR FOSTAMATINIB \n* CO’S WEBSITE HAS BEEN CORRECTED Source text for Eikon: Further company coverage:",
    "published": "2018-04-12T23:03:00.000+03:00",
    "crawled": "2018-04-12T23:13:11.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "make",
        "statement",
        "regarding",
        "website",
        "error",
        "reuters",
        "staff",
        "april",
        "reuters",
        "rigel",
        "pharmaceutical",
        "inc",
        "rigel",
        "make",
        "statement",
        "regarding",
        "website",
        "error",
        "fda",
        "continuing",
        "review",
        "nda",
        "pdufa",
        "action",
        "date",
        "fostamatinib",
        "nda",
        "april",
        "due",
        "error",
        "inaccurate",
        "information",
        "displayed",
        "regarding",
        "fda",
        "review",
        "nda",
        "fostamatinib",
        "co",
        "website",
        "corrected",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}